VST reports Q2 results on August 7 after a week that has reshuffled the positioning picture — bears have already retreated, the stock has drifted lower since, and the debate has shifted squarely to whether the fundamental story justifies a re-rating.
The short squeeze that defined the run-up to the August 5 report has run its course. Short interest fell from around 15.4 million shares in late July to roughly 12.3 million — 3.6% of free float — and has barely moved since, suggesting the covering wave is largely exhausted. Borrow conditions remain loose: the cost to borrow has ticked up 54% on the week to 0.45%, but that figure is still negligible in absolute terms. Availability is effectively unconstrained, with 335 million shares available against a short book of 12 million. The ORTEX short score has settled at 34.8, down sharply from 38 two weeks ago. Options are equally calm: the put/call ratio is 0.90, barely above its 20-day average of 0.89 and well below its 52-week high of 1.72. Together, the borrow and options markets describe a stock with no meaningful short squeeze fuel and no unusual demand for downside protection — a neutral positioning backdrop ahead of the number.
The bull-versus-bear argument is fundamentals-driven rather than technical. Bulls point to the Cogentrix acquisition lifting EBITDA forecasts by roughly 7%, and management's target of converting 60%-plus of adjusted EBITDA into free cash flow from 2026. The stock's EPS surprise rank at the 93rd percentile of the ORTEX universe adds weight to the idea that VST tends to beat. Analysts remain broadly constructive: Morgan Stanley raised its target to $212 late last month, while UBS and TD Cowen trimmed modestly — from $233 to $227 and $230 to $222, respectively — holding Buy ratings throughout. The consensus target is $223, implying roughly 58% upside to the current price of $140.58. Bears counter that the stock is still down approximately 30% from its peak despite positive catalysts, citing commodity cost volatility that inflicted an estimated $1.6 billion drag on adjusted EBITDA. The stock has fallen 7% over the past month and 1.6% on the week, underperforming the modestly positive moves in peers and . Closest correlated peer gained 4.3% on the week while VST gave up ground — a quiet divergence worth watching.
The insider tape adds a cautious undertone. Every recent transaction on record has been a sale. The independent chairman sold $4 million of stock in mid-June at $160. The Chief Accounting Officer sold nearly $1.6 million across two transactions in May and June. The CEO sold $1.6 million in March. Net insider sales over 90 days total roughly $9.3 million. None of these carry high trade-significance scores, and many may reflect pre-arranged plans, but the consistent direction — selling into a price that is now materially lower — adds modest signal to the cautious side of the ledger.
The last VST earnings print, in May, produced a 6.7% single-day decline and a 10.4% five-day drop. The August 7 report is therefore less a test of whether Vistra can grow and more a test of whether the Cogentrix integration and free cash flow conversion story is on track at a price point that has already moved well below where most analysts model fair value.
See the live data behind this article on ORTEX.
Open VST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
